Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis

• Status: Recruiting
• Trial end date: 2023-08-07
• Target enrollment: 0
• Participant gender: All

Summary

A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NYU Langone Health

Criteria

Inclusion Criteria:

1. Patients between 18 and 75 years of age

2. Patients undergoing shoulder arthroscopy with open subpectoral biceps tenodesis

Exclusion Criteria:

1. Patients younger than 18 and older than 75;

2. Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer;

3. Patients who are allergic to oxycodone;

4. Patients with diagnosed or self-reported cognitive dysfunction;

5. Patients with a history of neurologic disorder that can interfere with pain sensation;

6. Patients with a history of drug or recorded alcohol abuse;

7. Patients who are unable to understand or follow instructions;

8. Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;

9. Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures;

10. Patients with a BMI over 45;

11. Any patient that the investigators feel cannot comply with all study related procedures;

12. NYU Langone Health students, residents, faculty or staff members.